See more : OSI Systems, Inc. (OSIS) Income Statement Analysis – Financial Results
Complete financial analysis of Rain Therapeutics Inc. (RAIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rain Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Flamemaster Corporation (FAME) Income Statement Analysis – Financial Results
- Apollo Commercial Real Estate Finance, Inc. (ARI) Income Statement Analysis – Financial Results
- R S Software (India) Limited (RSSOFTWARE.NS) Income Statement Analysis – Financial Results
- Northeast Electric Development Company Limited (0042.HK) Income Statement Analysis – Financial Results
- ELMO Software Limited (ELO.AX) Income Statement Analysis – Financial Results
Rain Therapeutics Inc. (RAIN)
About Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 61.40M | 40.77M | 15.37M | 7.29M |
| General & Administrative | 15.74M | 10.74M | 3.59M | 3.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.74M | 10.74M | 3.59M | 3.54M |
| Other Expenses | 0.00 | 1.00K | -2.02M | -251.00K |
| Operating Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Cost & Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Interest Income | 1.42M | 119.00K | 32.00K | 209.00K |
| Interest Expense | 0.00 | 0.00 | 135.00K | 32.00K |
| Depreciation & Amortization | 80.00K | 120.00K | -1.94M | -14.00K |
| EBITDA | -77.06M | -51.51M | -18.91M | -10.84M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -77.14M | -51.51M | -18.96M | -10.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | 120.00K | -2.13M | -74.00K |
| Income Before Tax | -75.72M | -51.39M | -21.08M | -10.90M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.00K | 2.00K | -1.89M | -219.00K |
| Net Income | -75.72M | -51.39M | -19.20M | -10.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.71 | -2.65 | -1.80 | -1.00 |
| EPS Diluted | -2.71 | -2.65 | -1.80 | -1.00 |
| Weighted Avg Shares Out | 27.99M | 19.41M | 10.66M | 10.66M |
| Weighted Avg Shares Out (Dil) | 27.99M | 19.41M | 10.66M | 10.66M |
SHAREHOLDER ALERT: Potential Recovery for Rain Oncology Inc. (RAIN) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Rain Oncology Inc. (NASDAQ:RAIN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
SHAREHOLDER ALERT: Potential Recovery for Rain Oncology Inc. (RAIN) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Rain Oncology Inc. (NASDAQ:RAIN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Rain Oncology Inc. (RAIN)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Rain Oncology Inc. (“Rain” or...
SHAREHOLDER ALERT: Potential Recovery for Rain Oncology Inc. (RAIN) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Rain Oncology Inc. (NASDAQ:RAIN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Rain Investors of a Lead Plaintiff Deadline of September 12, 2023
NEW YORK , Sept. 11, 2023 /PRNewswire/ -- Attention Rain Oncology Inc. ("Rain") (NASDAQ: RAIN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between July 20, 2021...
SHAREHOLDER ALERT: Potential Recovery for Rain Oncology Inc. (RAIN) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / September 10, 2023 / If you suffered a loss on your Rain Oncology Inc. (NASDAQ:RAIN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
SHAREHOLDER ALERT: Potential Recovery for Rain Oncology Inc. (RAIN) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / September 10, 2023 / If you suffered a loss on your Rain Oncology Inc. (NASDAQ:RAIN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit
BENSALEM, Pa. , Sept. 8, 2023 /PRNewswire/ -- Law Offices of Howard G.
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Rain Oncology Inc.(RAIN) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Sept. 7, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN) of a class action securities lawsuit.
RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit
LOS ANGELES , Sept. 5, 2023 /PRNewswire/ -- The Law Offices of Frank R.
Source: https://incomestatements.info
Category: Stock Reports